Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (the "Company") on February 28, 2018, reporting events occurring on February 27, 2018. The Company is an emerging growth company incorporated in Delaware. The report details a material definitive agreement entered into by Napo Pharmaceuticals, Inc., a wholly-owned subsidiary of the Company.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial data point disclosed relates to a debt payoff condition:
- Debt Payoff Trigger: The Company agreed to pay all outstanding obligations under the "Second Tranche Notes" (including accrued interest) within three days of receiving proceeds of $5.0 million or more from one or more equity financings.
- Payment Deadline: Payment must be made no later than April 15, 2018.
Material Changes
The material change reported is the entry into a Consent and Payoff Agreement with purchasers of the Company's exchangeable promissory notes issued on April 27, 2017. Key terms include:
- Waiver of Exchange Rights: Purchasers agreed not to exercise their right to exchange the Second Tranche Notes for shares of Common Stock.
- Prepayment Restriction Waiver: Purchasers waived restrictions on the prepayment of the notes.
- Share Cap: Until the payment date, the Company must limit the total number of outstanding voting common shares to a specified amount, subject to limited exceptions.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of general risks. The primary contingency identified is the Company's ability to secure equity financing proceeds of at least $5.0 million to satisfy the debt payoff obligation by the April 15, 2018 deadline. Failure to meet this condition could result in the notes being exchanged for equity or other default consequences not detailed in this summary.
Investor Verification Checklist
- Verify the total outstanding principal and accrued interest on the Second Tranche Notes to assess the full liability.
- Confirm the specific share count limit imposed on the Company until the Payment Date.
- Monitor the Company's progress in securing the required $5.0 million in equity financing proceeds.
- Review the full text of the Consent and Payoff Agreement (Exhibit 10.1) for detailed covenants and exceptions.